Page last updated: 2024-11-12
antarelix
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
antarelix: a synthetic decapeptide, water-soluble LHRH antagonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 16135076 |
| MeSH ID | M0224142 |
Synonyms (21)
| Synonym |
|---|
| teverelix [inn] |
| n-acetyl-3-(2-naphthyl)-d-alanyl-p-chloro-d-phenylalanyl-3-(3-pyridyl)-d-alanyl-l-seryl-l-tyrosyl-n(sup 6)-carbamoyl-d-lysyl-l-leucyl-n(sup 6)-isopropyl-l-lysyl-l-prolyl-d-alaninamide |
| 151272-78-5 |
| unii-d19v7048jk |
| d19v7048jk , |
| d 23234 |
| d-23234 |
| ac-d-nal-d-cpa-d-pal-ser-tyr-d-hci-leu-lys(ipr)-pro-d-ala-nh2 |
| ep 24332 |
| ep-24332 |
| teverelix |
| d-alaninamide, n-acetyl-3-(2-naphthalenyl)-d-alanyl-4-chloro-d-phenylalanyl-3-(3-pyridinyl)-d-alanyl-l-seryl-l-tyrosyl-n6-(aminocarbonyl)-d-lysyl-l-leucyl-n6-(1-methylethyl)-l-lysyl-l-prolyl- |
| antarelix |
| DB05624 |
| Q27275967 |
| CS-0025196 |
| n-acetyl-3-(2-naphthalenyl)-d-alanyl-4-chloro-d-phenylalanyl-3-(3-pyridinyl)-d-alanyl-l-seryl-l-tyrosyl-n6-(aminocarbonyl)-d-lysyl-l-leucyl-n6-(1-methylethyl)-l-lysyl-l-prolyl-d-alaninamide |
| n-acetyl-3-(2-naphthalenyl)-d-alanyl-4-chloro-l-phenylalanyl-3-(3-pyridinyl)-d-alanyl-l-seryl-l-tyrosyl-n6-(aminocarbonyl)-d-lysyl-l-leucyl-n6-(1-methylethyl)-l-lysyl-l-prolyl-d-alaninamide |
| HY-105173 |
| DTXSID301033772 |
| AKOS040749635 |
Research Excerpts
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "Antarelix treatment significantly reduced the percentage of follicles > 2.00 mm in diameter in RF+ but not in R+2 ewes." | ( Effects of the Booroola Fec gene on ovarian follicular populations in superovulated Romanov ewes pretreated with a GnRH antagonist. Cognié, Y; Dufour, JJ; Mariana, JC; Mermillod, P; Romain, RF, 2000) | 1.03 |
Pharmacokinetics
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " After 5 mg teverelix, testosterone suppression <1 ng/mL started a median of 12 hours after dosing and lasted for a median of 33 hours." | ( Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men--a first-dose-in-humans study. Engel, J; Erb, K; Hermann, R; Pechstein, B; Schueler, A, 2000) | 0.31 |
| " The dosage of Antarelix was increased to 5 mg for each injection in EXP III (n = 6)." | ( Gonadotropin release in periovulatory heifers after GnRH analogs measured by two types of immunoassays. Bambang Poernomo, S; Becker, F; Bellmann, A; Kanitz, W; Nürnberg, G; Rehfeldt, C; Schneider, F, 2002) | 0.67 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (43)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (32.56) | 18.2507 |
| 2000's | 27 (62.79) | 29.6817 |
| 2010's | 1 (2.33) | 24.3611 |
| 2020's | 1 (2.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (4.35%) | 5.53% |
| Reviews | 3 (6.52%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 41 (89.13%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Clinical Trials (2)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I, Open-label, Single Centre Study Investigating the PK, Safety and PD of a Single Dose of Teverelix TFA, a GnRH Antagonist, Via s.c. or i.m. Route of Administration in Healthy Male Volunteers [NCT03781947] | Phase 1 | 48 participants (Actual) | Interventional | 2018-11-19 | Completed | ||
| An Adaptive Phase 2, Open-Label, Multicentre Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix Trifluoroacetate, a GnRH Antagonist, in Participants With Advanced Prostate Cancer [NCT04693507] | Phase 2 | 50 participants (Actual) | Interventional | 2021-03-04 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||